Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Vaxneuvance by Year
Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. reported growth YoY (%) (%)
Merck Vaxneuvance: 0.0% in FY2025, up 18.0 pts from a year earlier.
Latest, FY2025
0.0%
Period ended Dec 31, 2025
Change on a year earlier
+18.0 pts
-18.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Vaxneuvance | 825 | 808 | 2 | 459 | 461 | 0 | 366 | 347 | 5”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaxneuvance (15-valent pneumococcal conjugate vaccine) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.0% | +18.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -18.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Merck Vaxneuvance (%), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vaxneuvance-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.